# OnCo record nct06111235 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06111235/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06111235", "NCT06111235" ;
  schema:name "A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT"@en ;
  schema:description "A phase 3 trial of Cretostimogene grenadenorepvec in bladder & urothelial cancer, run by CG Oncology, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06111235/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06111235> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-12-14" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/> ;
  onco:technologies <https://onco.cc/technologies/oncolytic-virus/> ;
  onco:drugs <https://onco.cc/drugs/cretostimogene/> ;
  onco:companies <https://onco.cc/companies/cg-oncology/> .